IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3802
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$837M
Bassil I. Dahiyat
Xencor, Inc. focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$XNCR Xencor Inc | 38 | 38 | 41 | 39 | - | - | -21.1% | -15.2% | 100.0% | -254.0% | -170.1% | 23.8% | 0.0% | 39.0x | $837M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Xencor Inc (XNCR) receives a "Avoid" rating with a composite score of 37.8/100. It ranks #3802 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Bassil I. Dahiyat
Chief Executive Officer
Labor Force
280
38
39
44
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for XNCR
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for XNCR.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROIC -35.8% vs WACC 9.0% (spread -44.8%)
GM 100% vs sector 43%, OM -254% vs sector 1%
Capital turnover 0.20x, R&D intensity 179.4%
Rev growth 24%, 10yr history
Interest coverage -6.2x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Xencor Inc with an Avoid rating, assigning a composite score of 37.8/100 and 1 out of 5 stars. Ranked #3802 of 7,333 stocks, XNCR falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
XNCR's quality score of 38/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -21.1% (sector avg: -2.5%), gross margins of 100.0% (sector avg: 42.5%), net margins of -170.1% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 41/100, XNCR appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 1.30x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Xencor Inc's investment score of 39/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 23.8% vs. a sector average of 5.9% and a return on assets of -15.2% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
XNCR is currently showing below-average momentum at 39/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 23.8% year-over-year, while a beta of 1.44 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
XNCR's stability score of 44/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.44 and a debt-to-equity ratio of 39.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Xencor Inc's short interest score of 14/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.44), elevated leverage (D/E: 39.00x), small-cap liquidity risk. At $837M (small-cap), XNCR carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Xencor Inc is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3802 of 7,333 overall (48th percentile). Key comparisons include ROE of -21.1% trailing the -2.5% sector median and operating margins of -254.0% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While XNCR currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Short Int. (14) would have the largest impact on the composite score.
ROE 750% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 135% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 19787% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Xencor Inc (XNCR) as Avoid with a composite score of 37.8/100 at a current price of $11.80. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in stability (44th percentile) and value (41th percentile), which together account for the majority of the composite score. Offsetting weakness in quality (38th percentile) and momentum (39th percentile) tempers our overall conviction. We assign a No Moat rating (36/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Xencor Inc holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 37.8/100 places it at rank #3802 in our full 7,333-stock universe. At $837M in market capitalization, Xencor Inc is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 24%, though momentum at the 39th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 100% (+57.5pp vs sector) narrow to operating margins of -254% (-255.2pp vs sector) and net margins of -170.1%, yielding a gross-to-net conversion rate of -170%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $11.80, Xencor Inc is trading near fair value based on current fundamentals. Our value factor score of 41/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/B of 1.3x, P/S of 7.5x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 100% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 24% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
The Avoid rating (composite 37.8/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -170.1% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
High beta of 1.44 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
We assign a High uncertainty rating to Xencor Inc. Key risk factors include elevated market sensitivity (beta of 1.44), current negative profitability (net margin -170.1%). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.44); current negative profitability (net margin -170.1%). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 44th percentile and quality factor at the 38th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Xencor Inc's capital allocation as Poor. Key concerns include low returns on equity (-21.1%), negative profitability, weak asset returns (ROA -15.2%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Xencor Inc significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Xencor Inc receives a Avoid rating with a composite score of 37.8/100 (rank #3802 of 7,333). Our quantitative framework assigns a No Moat (36/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 40/100.
Our analysis does not support a constructive view on Xencor Inc at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Xencor Inc a meaningful economic moat, scoring 36/100 on our composite assessment. The ROIC-WACC spread of -44.8% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 12.9/20.
The strongest moat sources are margin superiority (12.9/20) and growth durability (8.6/20). GM 100% vs sector 43%, OM -254% vs sector 1%. Rev growth 24%, 10yr history. These pillars form the core of Xencor Inc's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0.1/20) and reinvestment efficiency (7/20). ROIC -35.8% vs WACC 9.0% (spread -44.8%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Xencor Inc's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 100% providing a solid profitability foundation, robust top-line growth of 24% expanding the revenue base. The margin cascade from 100% gross to -254% operating to -170.1% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 38th percentile.
The margin profile shows gross margins of 100%, operating margins of -254%, net margins of -170.1%. Return metrics include ROE of -21.1% and ROA of -15.2%. Relative to the Manufacturing sector, gross margins are 57.5 percentage points above the sector median of 43%, and ROE of -21.1% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 39%, revenue growth of 24%. The sector median D/E is 0%, putting Xencor Inc at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.

Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Key Insights Xencor's estimated fair value is US$16.09 based on 2 Stage Free Cash Flow to Equity Xencor's US$11.62...
Xencor’s fair value estimate has been nudged up from about US$28.25 to roughly US$28.83 per share, with a slightly higher discount rate of around 7.50% and a modest lift in revenue growth assumptions to roughly 4.13%. These changes line up with a more supportive backdrop for U.S. biopharma, where stronger sector conditions, steadier deal activity and better access to capital are now being recognized in updated models, even as questions remain about how long these supports will hold. Stay...
Xencor Inc. (NASDAQ:XNCR) is one of the best high short interest stocks with biggest upside potential.

In the latest quarter, 5 analysts provided ratings for Xencor (NASDAQ:XNCR), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 1 2 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $35.4, a high estimate of $40.00, and a low estimate of $31.00. A decline of 17.29% from the prior average price target is evident in the current average. Investigating Analyst Ratings: An Elaborate Study A clear picture of Xencor's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Sean McCutcheon Raymond James Lowers Strong Buy $40.00 $58.00 Etzer Darout BMO Capital Lowers Outperform $32.00 $34.00 Gregory Renza RBC Capital Lowers Outperform $31.00 $32.00 David Nierengarten Wedbush Raises Outperform $36.00 $34.00 Kaveri Pohlman BTIG Lowers Buy $38.00 $56.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Xencor. This insight gives a snapshot of analysts' perspectives on the current state of the ...Full story available on Benzinga.com
Above 50MA
37.18%
Net New Highs
+51081